Skip to main content
Premium Trial:

Request an Annual Quote

Exelixis Reports Increase in Q4 Revenues; R&D Spending Swells

NEW YORK, March 21 - Exelixis on Wednesday said that increased corporate collaborations helped boost fourth-quarter revenue to $12.8 million from $7.1 million posted during the same time last year.


For the period ended Dec. 31, R&D spending also rose, to $21.8 million from $13.3. million year over year. The company said that staff increases and facility expansions designed to support new partnerships and boost drug-discovery efforts helped spur the surge.


Exelixis also reported a widened pro forma net loss, which jumped to $12.7 million, or $.26 per share, from $7.7 million, or $.18 per share in the year-ago period. These figures excluded non-cash charges. Net loss including those charges were $18.3 million, or $.38 per share, compared with $48 million, or $1.13 per share on year ago.


Exelixis said it has roughly $227.7 million in cash and investments as of Dec. 31, some $109.6 million of it through its acquisition of Genomica. Exelixis had $112.6 million in cash and investments one year ago and said it expects its cash balance in 2002 to exceed $154 million.


Looking forward, the company said it anticipates revenues to increase between 20 percent and 25 percent in the current year. Operating expenses, excluding non-cash charges, will also swell in 2002 between 40 percent and 50 percent year over year.

Exelixis said it expects its cash-burn rate in 2002 to grow to between $68 million and $73 million, driven largely by investments in drug discovery, including clinical development, manufacturing, and "support of a worldwide research infrastructure." The firm burned approximately $41.5 million in 2001.

The Scan

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.

Algorithm Teases Out Genetic Ancestry in Individuals at Biobank Scale

Researchers develop an algorithm known as Rye to tease apart ancestry fractions in admixed individuals at a biobank-scale, applying it to 488,221 UK Biobank participants in Nucleic Acids Research.

Multi-Ancestry Analysis Highlights Comparable Common Variants at Complex Trait-Linked Loci

Researchers in Nature Genetics examine common variants implicated in more than three dozen conditions, estimating genetic effect similarities across ancestry tracts in admixed individuals.

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.